A study examining the utility of inhaled mannitol as an additional therapy during an admission to hospital for an acute pulmonary exacerbation in children with cystic fibrosis

This study is testing whether adding inhaled mannitol (a dry powder that helps loosen and clear mucus from the airways) as an extra therapy during a hospital admission for a lung infection flare-up improves outcomes for children with cystic fibrosis (CF). CF causes thick, sticky mucus to build up in the lungs, making infections more common and harder to treat. Researchers want to see whether adding mannitol to the standard intravenous antibiotic treatment helps children's lungs recover better and faster. You may be eligible if: - Your child is at least 6 years old and under 18 years of age - Your child has been admitted to hospital with a lung infection flare-up (pulmonary exacerbation) that requires intravenous antibiotics - Your child's lung function (FEV1) is at least 40% of predicted for their age You may NOT be eligible if: - Your child started oral steroids at admission or started a new mucus-clearing drug within 3 months of admission - Your child requires oxygen or is planned to have surgery during this admission - Your child has significant coughing of blood (haemoptysis) during the current flare-up Talk to your doctor about whether this trial might be right for you.